Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- Deprescribing CV medications may benefit elderly patients with evolving treatment goals Darlene Dobkowski, MA
-
- Complex PCI: Who and where? Darshan Doshi, MD, MS; Robert F. Riley, MD, MS, FACC, FAHA, FSCAI
- Assessing for myocarditis may clarify whether athletes can return to sports after COVID-19 Darlene Dobkowski, MA
- Disparities in cardiometabolic mortality worsened since 1999 Darlene Dobkowski, MA
- Ketogenic, intermittent fasting diets may be heart-healthy Erik Swain
- Plant-based meat products reduce trimethylamine-N-oxide, other CVD risk factors Darlene Dobkowski, MA
- Smoking cessation after MI lowers mortality risk in young adults Darlene Dobkowski, MA
- Trends in BP control highlight age, race disparities in hypertension treatment, education Scott Buzby
- Updating appropriate use criteria, enforcing False Claims Act may reduce inappropriate PCI Darlene Dobkowski, MA
-
- Smartwatch app to detect AF receives FDA clearance Darlene Dobkowski, MA
- European group: E-cigarette use should be limited due to CV effects Erik Swain
- Hostility may predict mortality in ACS Darlene Dobkowski, MA
- Women comprise 10.1% of CV clinical trial leadership Darlene Dobkowski, MA
- COLCOT: Early use of colchicine beneficial after MI Erik Swain
- Cryoballoon ablation may be better first-line treatment vs. drug therapy in paroxysmal AF Erik Swain
- Studies find hypertension most prevalent comorbidity in patients hospitalized for COVID-19 Darlene Dobkowski, MA
- Icosapent ethyl reduces coronary plaque at 18 months: EVAPORATE final results Katie Kalvaitis
-
- IL-6 receptor inhibitor improves myocardial salvage in STEMI: ASSAIL-MI Darlene Dobkowski, MA
- Mavacamten improves outcomes in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM Scott Buzby; Katie Kalvaitis
- Mixed beliefs, practices affect hypertension diagnoses Darlene Dobkowski, MA
- Naps longer than 1 hour may confer risk for CVD, mortality Erik Swain
- Sacubitril/valsartan for HFpEF reduces NT-proBNP, but no effect on functional outcomes Darlene Dobkowski, MA
- ASSAIL-MI
- BAMI
- BRACE CORONA
-
- CASA-AF
- ELDERCARE-AF
- HOST-REDUCE-POLYTECH-ACS
- ISAR PLASTER
- POPular CABG